GI Windows Announces Data from First-Ever Clinical Study on a New Non-surgical Procedure to Treat Type 2 Diabetes with Self-Assembling Magnets at Digestive Disease Week® 2016

Six-Month Data Support Incision-less Anastomosis
System’s Safety and Efficacy in Treating Type 2 Diabetes

New Therapy is First of its Kind with Endoscopic Delivery and the Promise
to Achieve Long-term Benefits  
Comparable to Metabolic Surgery 

 

West Bridgewater, Mass., May 24, 2016 — GI Windows, Inc., a clinical-stage medical device company, today announced the presentation of six-month results of the first-ever clinical study evaluating the endoscopic creation of a dual-path enteral diversion using the company’s Incision-less Anastomosis System (IAS) at Digestive Disease Week® 2016 (DDW), in San Diego, Calif. The data support the safety and efficacy of GI Windows’ IAS as a treatment option for Type 2 diabetes in obese patients.

Read More

{snp_edit_page}

GI Windows to Present First-Ever Clinical Series Data on a Novel Non-Surgical Procedure To Treat Type 2 Diabetes at Digestive Disease Week® 2016

Three Presentations Will Highlight the GI Windows Incision-less Anastomosis System

May 16, 2016 

WEST BRIDGEWATER, Mass.--(BUSINESS WIRE)--GI Windows, Inc., a clinical-stage medical device company, today announced that the company will debut its innovative new approach to managing Type 2 diabetes at Digestive Disease Week® 2016 (DDW), taking place May 21-24 in San Diego, Calif. The company will deliver three presentations at DDW, showcasing data and video of its Incision-less Anastomosis System (IAS). Among the highlights is a presentation on the six-month results of the first-ever clinical series evaluating the endoscopic creation of a dual-path enteral diversion using the IAS.

Read More

{snp_edit_page}